Pressure BioSciences, Inc. develops pressure cycling technology (PCT) solutions. Its PCT technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, such as cells and tissues from human, animal, plant, and microbial sources. The company offers Barocycler instrumentations, including Barocycler 2320EXT, Barozyme-HT48, Barocycler NEP3229, HUB440, HUB880, and The Shredder SG3. It also distributes cell disruption equipment, parts, and consumables. In addition, the company offers Barocycler consumable products, such as PCT MicroTubes, PCT-MicroCaps, PCT-Micro-Pestle, PULSE Tubes, and BaroFlex 8-well Processing Strips, as well as application specific kits. Pressure BioSciences, Inc. serves researchers at academic laboratories; government agencies; and biotechnology, pharmaceutical, and other life sciences institutions in the United States, Europe, and Asia. Pressure BioSciences, Inc. has a collaboration with NutraFuels, Inc. for the development of water-soluble Nanoemulsion-based nutraceuticals. The company was formerly known as Boston Biomedica, Inc. Pressure BioSciences, Inc. was founded in 1978 and is based in South Easton, Massachusetts.
Industry, Sector and Symbol
Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
Phone508-230-1828
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.46 million
Profitability
Miscellaneous
Employees17
Next Earnings Date5/28/2019 (Estimated)
OptionableNot Optionable
Pressure Biosciences (OTCMKTS:PBIO) Frequently Asked Questions
What is Pressure Biosciences' stock symbol?
Pressure Biosciences trades on the OTCMKTS under the ticker symbol "PBIO."
How were Pressure Biosciences' earnings last quarter?
Pressure Biosciences Inc (OTCMKTS:PBIO) posted its quarterly earnings data on Tuesday, May, 15th. The company reported ($1.64) earnings per share (EPS) for the quarter. The company earned $0.61 million during the quarter. View Pressure Biosciences' Earnings History.
When is Pressure Biosciences' next earnings date?
Has Pressure Biosciences been receiving favorable news coverage?
Media coverage about PBIO stock has been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Pressure Biosciences earned a daily sentiment score of -1.8 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 9.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near term.
Who are some of Pressure Biosciences' key competitors?
Some companies that are related to Pressure Biosciences include Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), PerkinElmer (PKI), Bio-Rad Laboratories (BIO.B), Bio-Rad Laboratories (BIO), Bruker (BRKR), Coherent (COHR), Horiba (HRIBF), Pacific Biosciences of California (PACB), Accelerate Diagnostics (AXDX), Fluidigm (FLDM), Quanterix (QTRX) and Eyepoint Pharmaceuticals (EYPT).
What other stocks do shareholders of Pressure Biosciences own?
Who are Pressure Biosciences' key executives?
Pressure Biosciences' management team includes the folowing people:
- Mr. Richard T. Schumacher, Founder, Pres, CEO, Treasurer, Clerk, Sec. & Director (Age 69)
- Dr. Alexander V. Lazarev, Chief Science Officer (Age 54)
- Dr. Edmund Y. Ting Ph.D., Sc.D. Ph.D., Sr. VP of Engineering (Age 64)
- Mr. Richard P. Thomley, Acting Chief Financial Officer (Age 67)
- Dr. Bradford Addison Young, Sr. VP & Chief Commercial Officer (Age 50)
How do I buy shares of Pressure Biosciences?
Shares of PBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pressure Biosciences' stock price today?
One share of PBIO stock can currently be purchased for approximately $3.06.
How big of a company is Pressure Biosciences?
Pressure Biosciences has a market capitalization of $5.71 million and generates $2.46 million in revenue each year. Pressure Biosciences employs 17 workers across the globe.
What is Pressure Biosciences' official website?
How can I contact Pressure Biosciences?
Pressure Biosciences' mailing address is 14 NORFOLK AVENUE, SOUTH EASTON MA, 02375. The company can be reached via phone at 508-230-1828 or via email at [email protected]
MarketBeat Community Rating for Pressure Biosciences (OTCMKTS PBIO)
MarketBeat's community ratings are surveys of what our community members think about Pressure Biosciences and other stocks. Vote "Outperform" if you believe PBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
